Halozyme acquires a biotech startup for up to $400 million, enhancing its drug delivery capabilities.
Author: PharmaSignal News Desk
Regenxbio gene therapy trials for Hunter and Hurler syndromes are suspended by the FDA due to safety concerns involving a brain tumor.
A senior BD execution signal from this month’s most instructive pharma deal.
Intellia CRISPR trial resumes after FDA hold lifted. New safeguards are in place following a participant’s death.
China drug licensing deals for early-stage prospects are expected to rise, focusing on cell and gene therapies.
Cormorant SPAC deal secures $150M for a new biotech merger, marking its third since 2022 amid a rebound in SPAC activity.
PharmaSignal Take This week’s events highlight a growing trend in the pharma industry towards strategic acquisitions and partnerships, particularly in the areas of immunotherapy and obesity treatment. Notable examples include Lilly’s acquisition of Ventyx and Corxel’s licensing deal for an obesity pill. These moves stress-test the assumption of platform scalability, suggesting a shift in post-approval decision-making towards a more integrated approach to product development and market access. This is the PharmaSignal Weekly Brief – Global Pharma Roundup, where we highlight the dominant themes of M&A activity, regulatory acceleration, and pipeline risk in the global pharma industry. M&A and Strategic Deals…
Corxel GLP-1 Obesity Pill receives $287M funding to support its development, licensed from Vincentage in China.
Bristol Myers partners with Janux in a deal worth up to $850 million, focusing on T cell engagers for cancer treatment.
FDA multiple myeloma drugs pathway accelerates approvals, allowing therapies to clear based on tumor cell elimination.